CURIS INC (CRIS)
US2312693094 - Common Stock
CRIS gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 564 industry peers in the Biotechnology industry. CRIS may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, CRIS is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
CRIS had negative earnings in the past year.
In the past year CRIS has reported a negative cash flow from operations.
In the past 5 years CRIS always reported negative net income.
CRIS had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
CRIS has a worse Return On Assets (-107.09%) than 78.10% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.09% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-47.14%
ROA(5y)-49.53%
ROE(3y)-137.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 98.68%, CRIS belongs to the top of the industry, outperforming 97.85% of the companies in the same industry.
CRIS's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for CRIS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.68% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
CRIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for CRIS has been increased compared to 1 year ago.
Compared to 5 years ago, CRIS has more shares outstanding
CRIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
CRIS has an Altman-Z score of -43.50. This is a bad value and indicates that CRIS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -43.50, CRIS is doing worse than 93.90% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -43.5 |
ROIC/WACCN/A
WACC10.61%
2.3 Liquidity
A Current Ratio of 1.22 indicates that CRIS should not have too much problems paying its short term obligations.
The Current ratio of CRIS (1.22) is worse than 84.74% of its industry peers.
CRIS has a Quick Ratio of 1.22. This is a normal value and indicates that CRIS is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of CRIS (1.22) is worse than 83.12% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.22 | ||
| Quick Ratio | 1.22 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.29% over the past year.
CRIS shows a small growth in Revenue. In the last year, the Revenue has grown by 0.38%.
CRIS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.79% yearly.
EPS 1Y (TTM)16.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.19%
Revenue 1Y (TTM)0.38%
Revenue growth 3Y-2.58%
Revenue growth 5Y-0.79%
Sales Q2Q%3.46%
3.2 Future
The Earnings Per Share is expected to grow by 12.94% on average over the next years. This is quite good.
CRIS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 43.27% yearly.
EPS Next Y21%
EPS Next 2Y22.11%
EPS Next 3Y15.33%
EPS Next 5Y12.94%
Revenue Next Year-6.38%
Revenue Next 2Y-11.34%
Revenue Next 3Y0.93%
Revenue Next 5Y43.27%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for CRIS. In the last year negative earnings were reported.
Also next year CRIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as CRIS's earnings are expected to grow with 15.33% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.11%
EPS Next 3Y15.33%
5. Dividend
5.1 Amount
No dividends for CRIS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
CURIS INC
NASDAQ:CRIS (1/3/2025, 8:00:01 PM)
After market: 3.86 -0.01 (-0.26%)3.87
-0.37 (-8.73%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners38.82%
Inst Owner Change-12.84%
Ins Owners0.16%
Ins Owner Change0%
Market Cap32.78M
Analysts80
Price Target21.42 (453.49%)
Short Float %0.57%
Short Ratio0.63
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.69%
Min EPS beat(2)-42.45%
Max EPS beat(2)-18.94%
EPS beat(4)2
Avg EPS beat(4)-12.56%
Min EPS beat(4)-42.45%
Max EPS beat(4)5.86%
EPS beat(8)5
Avg EPS beat(8)-5.42%
EPS beat(12)6
Avg EPS beat(12)-4.4%
EPS beat(16)7
Avg EPS beat(16)-5.44%
Revenue beat(2)2
Avg Revenue beat(2)23.56%
Min Revenue beat(2)20.95%
Max Revenue beat(2)26.17%
Revenue beat(4)2
Avg Revenue beat(4)4.89%
Min Revenue beat(4)-15%
Max Revenue beat(4)26.17%
Revenue beat(8)3
Avg Revenue beat(8)-0.52%
Revenue beat(12)4
Avg Revenue beat(12)-2.96%
Revenue beat(16)6
Avg Revenue beat(16)-3.03%
PT rev (1m)0%
PT rev (3m)-6.67%
EPS NQ rev (1m)0%
EPS NQ rev (3m)23.57%
EPS NY rev (1m)-0.29%
EPS NY rev (3m)3.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-25.86%
Revenue NY rev (1m)7.64%
Revenue NY rev (3m)3.48%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 3.2 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | N/A | ||
| P/tB | N/A | ||
| EV/EBITDA | N/A |
EPS(TTM)-7.81
EYN/A
EPS(NY)-4.56
Fwd EYN/A
FCF(TTM)-4.78
FCFYN/A
OCF(TTM)-4.78
OCFYN/A
SpS1.21
BVpS-1.03
TBVpS-2.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -107.09% | ||
| ROE | N/A | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 98.68% | ||
| FCFM | N/A |
ROA(3y)-47.14%
ROA(5y)-49.53%
ROE(3y)-137.58%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1%
GM growth 5Y0.68%
F-Score4
Asset Turnover0.24
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.22 | ||
| Quick Ratio | 1.22 | ||
| Altman-Z | -43.5 |
F-Score4
WACC10.61%
ROIC/WACCN/A
Cap/Depr(3y)60.87%
Cap/Depr(5y)139.82%
Cap/Sales(3y)1.38%
Cap/Sales(5y)2.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)16.29%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20.19%
EPS Next Y21%
EPS Next 2Y22.11%
EPS Next 3Y15.33%
EPS Next 5Y12.94%
Revenue 1Y (TTM)0.38%
Revenue growth 3Y-2.58%
Revenue growth 5Y-0.79%
Sales Q2Q%3.46%
Revenue Next Year-6.38%
Revenue Next 2Y-11.34%
Revenue Next 3Y0.93%
Revenue Next 5Y43.27%
EBIT growth 1Y-2.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.79%
EBIT Next 3Y-6.28%
EBIT Next 5Y-9.65%
FCF growth 1Y20.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.41%
OCF growth 3YN/A
OCF growth 5YN/A